M. Carrasco-Alfonso

发表

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

B. Monk, I. Vergote, S. Pignata, 2019, Gynecologic oncology.

Online Nanoflow Multidimensional Fractionation for High Efficiency Phosphopeptide Analysis*

James T. Webber, Brijesh K. Garg, S. Ficarro, 2011, Molecular & Cellular Proteomics.

C/EBPα and DEK coordinately regulate myeloid differentiation.

James T. Webber, D. Tenen, S. Ficarro, 2012, Blood.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants

M. Daly, B. Bernstein, K. Farh, 2014, Nature.

and DEK coordinately regulate myeloid differentiation α C/EBP

James T. Webber, D. Tenen, S. Ficarro, 2012 .

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, J. Goldberg, 2020 .

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

R. Motzer, M. Oya, I. Davis, 2018, Journal of Hematology & Oncology.

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

H. Goldschmidt, H. Einsele, M. Vogel, 2021 .

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

S. Jagannath, A. Jakubowiak, P. Hari, 2021 .

CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma

H. Einsele, M. Vogel, B. Arnulf, 2021 .

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.